These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33440670)

  • 21. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 22. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
    O'connor CT; Kiernan TJ; Yan BP
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):725-739. PubMed ID: 28571507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
    Ašić A; Marjanović D; Mirat J; Primorac D
    Per Med; 2018 May; 15(3):209-221. PubMed ID: 29767545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on laboratory assessment for direct oral anticoagulants (DOACs).
    Gosselin RC; Adcock DM; Douxfils J
    Int J Lab Hematol; 2019 May; 41 Suppl 1():33-39. PubMed ID: 31069969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of
    Wang Y; Chen M; Chen H; Wang F
    Front Pharmacol; 2021; 12():639854. PubMed ID: 33935730
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
    Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
    High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
    Gouveia F; Bicker J; Santos J; Rocha M; Alves G; Falcão A; Fortuna A
    J Pharm Biomed Anal; 2020 Mar; 181():113109. PubMed ID: 31981828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
    Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
    Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
    Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
    Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
    Mbatchi LC; Gassiot M; Pourquier P; Goberna A; Mahammedi H; Mourey L; Joly F; Lumbroso S; Evrard A; Houede N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):653-659. PubMed ID: 28676933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
    Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
    Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.
    Pottegård A; Grove EL; Hellfritzsch M
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):174-181. PubMed ID: 29141274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.